Rays Power Infra announced closure of INR 127 Crore Equity Capital Fund Raise - “Urban Whispers” An Exhibition of Paintings will be displayed by renowned artist Ajit Deswandikar at Jehangir Art Gallery in Mumbai - ARTIVAL FOUNDATION Presents "ART CONTINUUM" An Exhibition of Paintings & Sculptures will displayed at Nehru Centre Art Gallery in Mumbai - Cancer Survivors Meet 2025 Celebrates Strength, Hope, and Resilience at HCG ICS Khubchandani Cancer Centre - Kalyan Jewellers Launches ‘Crafting Futures’ Initiative to Uplift Artisans This initiative is dedicated to improving the livelihoods of jewellery artisans - Hexaware Technologies Limited Announced its Initial public offering (IPO) to open on Wednesday, February 12, 2025 Sets Price Band fixed at ₹ 674 per equity share to ₹ 708 per equity share of the face value of ₹1 each - Ajax Engineering Limited Announced its Initial public offering to open on Monday, February 10, 2025 Sets Price Band fixed at ₹ 599 per equity share to ₹ 629 per equity share of the face value of ₹1 each - Cyber for HER’ Hackathon witnessed enthusiastic participation from women throughout India, Cyber for HER is a capacity building initiative dedicated to empowering young women aged 18 to 23 in the field of cybersecurity - pollo Cancer Centre Navi Mumbai launches nationwide campaign to fight against cancer Unify to Notify’-- Urges Government to Classify Cancer a Notifiae Disease in India - Tata Play Collaborates with Salesforce to Drive AI-Powered Customer Experience, Tata Play will redefine customer engagement with hyper-personalized experiences and actionable insights - Brigade Hotel Ventures Limited gets SEBI nod for IPO

Digital transformation and R&D to determine the future of Pharma industry: Simon Gallagher, (Interim) General Manager at Takeda, India

Mumbai, 27th December (GNI): India’s domestic pharmaceutical market is estimated at US$ 42 billion in 2021 and likely to reach US$ 65 billion by 2024 and further expand to ~US$ 120-130 billion by 2030.[1] The ‘pharmacy of the world’ holds the potential to alter the quality of life in the world with its large talent pool of researchers, engineers, and doctors. When put to the test under the pandemic, the domestic industry worked closely with the global ecosystem to develop therapies and vaccines to control the spread of the deadly virus. Forecasting the future of the healthcare and pharma industry, Simon Gallagher, General Manager (Interim), Takeda India, said that the same truly global spirit of collaborations and partnerships should guide the future of the pharma industry that can change the healthcare infrastructure of the entire nation.

As the year 2022 unfolds, the industry can be seen realigning efforts towards developing cures and treatments for other diseases. Discourse on prioritizing treatment for rare diseases has gained prominence and is expected to develop further in the forthcoming years.

Commenting on the upcoming trends in the pharma industry, Simon Gallagher, (Interim) General Manager at Takeda, India, said, The pharmaceutical sector became more focused on innovation and technology over the past two years of change. A huge phygital (physical + digital) transition was witnessed with the emergence of a hybrid model of engagement with Health Care Professionals. In the coming years, the industry is expected to level up digital capabilities and technology adoption to create personalized tools for patient care. The opportunity lies in improving virtual tools to build immersive patient experiences. The future of pharmaceuticals is dependent on industry research and development, not just to combat COVID-19 but also to combat other diseases. The power of innovation shall help the industry unlock ways to make quality care more accessible and shall pave the way for better medications and pharmaceutical instruments.

An emerging focus can be seen towards leveraging data and digital across all levels to understand patient journeys better and simplify the treatment processes. Against traditional medicine, the coming years are expected to witness investments in cell and gene therapies to change the course of acquired human diseases, stated in the press release.

Despite numerous upcoming therapies, the past two years have taught us that the key to advancing healthcare in India would remain to make quality care accessible to the underserved communities. The years to come can thus see the pharmaceutical companies working closely with the public sector to bridge infrastructural gaps to enhance timely diagnosis through widespread awareness, collaborating to create a mindset for research, and bringing in innovations to fulfill the healthcare needs. Ends

Be the first to comment on "Digital transformation and R&D to determine the future of Pharma industry: Simon Gallagher, (Interim) General Manager at Takeda, India"

Leave a comment

Your email address will not be published.


*